AGC Biologics in Bothell to produce new diabetes treatment
The contract drug manufacturer paired with drug developer Provention Bio to bring the new therapy to market. BOTHELL — A new treatment shown to del...
The contract drug manufacturer paired with drug developer Provention Bio to bring the new therapy to market. BOTHELL — A new treatment shown to delay the onset of Type 1 diabetes by two years will be manufactured at a biotech's campus in Bothell. Provention Bio, a New Jersey based pharmaceutical company, developed the treatment known as Tzield (teplizumab-mzwv). AC Biologics, which is headquartered in Bothell, will produce it for commercial distribution. AGC is a contract development and manufacturing company that provides drug development and manufacturing services to pharmaceutical companies.